Ubiquitin-like protein D enhances the sensitivity of MDA-MB-231 cells to cisplatin via the Bcl-2/Bax/caspase-3 pathway in triple-negative breast cancer

被引:0
作者
Ren, Aijun [1 ]
机构
[1] Peoples Hosp Yucheng, Dept Oncol, 73 Kaituo Rd, Yucheng, Shandong, Peoples R China
关键词
UBD; triple negative breast cancer; cisplatin; MDA-MB-231; RESISTANCE; DEGRADATION; MCL-1;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: To study the effects of ubiquitin-like protein D (UBD) expression on the sensitivity of cisplatin to human triple negative breast cancer MDA-MB-231 cells. Methods: Thirty-five cases of triple negative breast cancer patients who were treated by chemotherapy with cisplatin and surgery in our hospital were divided into a CR group and PR group according to postoperative pathological diagnosis. Expression of UBD was compared before chemotherapy and UBD over expression and silenced expression were generated in MDA-MB-231 cells. The expression of UBD, Bax, Bcl-2, and caspase-3 were compared and the IC50 to cisplatin was determined in different MDA-MB-231 cells. Results: The positive cell ratio of UBD and Bcl-2 was (20.8+ 7.9%) and (41.3+ 12.9%) respectively in tumor tissue of the CR group, which was significantly lower than the PR group (68.3+ 12.4%) and (77.8+ 20.4%) (P< 0.05). The positive cell ratio of Bax and activated caspase-3 was (56.9+ 15.7%) and (67.3+ 21.4%) respectively in tumor tissue of the CR group, which was significantly higher than the PR group that was (30.6+ 11.5%) and (36.6+ 10.1%) (P< 0.05). The IC50 of cisplatin in 231-Silence, MDA-MB-231, and 231-Over was (19.82+ 1.08) mu mol/L, (35.69+ 1.21) mu mol/L and (67.79+ 1.54) mu mol/L respectively. The relative expression of Bcl-2 in MDA-MB-231 cells was (0.66+ 0.17), which was significantly higher than 231-Silence (0.075+ 0.05) (P< 0.05), and significantly lower than 231-Over (1.05+ 0.22) (P< 0.05). The relative expression of Bax and activated caspase-3 in MDA-MB-231 cells was (0.44+ 0.10) and (0.70+ 0.19) respectively, which was significantly lower than 231-Silence [(1.08+ 0.24) and (1.28+ 0.31)] (P< 0.05) and significantly higher than 231-Over [(0.17+ 0.09) and (0.36+ 0.12)] (P< 0.05). Conclusion: The high expression of UBD enhanced the resistance of cisplatin to MDA-MB-231, and the mechanism may be related to the high expression of UBD reduced Bax and caspase-3 gene expression and increased Bcl-2 gene expression.
引用
收藏
页码:1932 / 1939
页数:8
相关论文
共 20 条
[1]   Emerging Bcl-2 inhibitors for the treatment of cancer [J].
Azmi, Asfar S. ;
Wang, Zhiwei ;
Philip, Philip A. ;
Mohammad, Ramzi M. ;
Sarkar, Fazlul H. .
EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (01) :59-70
[2]   Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells [J].
Cha, Tai-Lung ;
Chuang, Mei-Jen ;
Wu, Sheng-Tang ;
Sun, Guang-Huan ;
Chang, Sun-Yran ;
Yu, Dah-Shyong ;
Huang, Shih-Ming ;
Huan, Steven Kuan-Hua ;
Cheng, Tse-Chou ;
Chen, Tzu-Ting ;
Fan, Pao-Luo ;
Hsiao, Pei-Wen .
CLINICAL CANCER RESEARCH, 2009, 15 (03) :840-850
[3]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[4]   RETRACTED: Apoptosis and Molecular Targeting Therapy in Cancer (Retracted Article) [J].
Hassan, Mohamed ;
Watari, Hidemichi ;
AbuAlmaaty, Ali ;
Ohba, Yusuke ;
Sakuragi, Noriaki .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[5]  
Jiang LN, 2016, LETT BIOTECHNOLOGY
[6]   An integrated view of cisplatin-induced nephrotoxicity and ototoxicity [J].
Karasawa, Takatoshi ;
Steyger, Peter S. .
TOXICOLOGY LETTERS, 2015, 237 (03) :219-227
[7]   Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin [J].
Liang, Sixian ;
Peng, Xun ;
Li, Xiaoli ;
Yang, Ping ;
Xie, Linhao ;
Li, Yaochen ;
Du, Caiwen ;
Zhang, Guojun .
ONCOTARGET, 2015, 6 (02) :1020-1030
[8]   Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J].
Liedtke, Cornelia ;
Mazouni, Chafika ;
Hess, Kenneth R. ;
Andre, Fabrice ;
Tordai, Attila ;
Mejia, Jaime A. ;
Symmans, W. Fraser ;
Gonzalez-Angulo, Ana M. ;
Hennessy, Bryan ;
Green, Marjorie ;
Cristofanilli, Massimo ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1275-1281
[9]   Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis [J].
Liu, Miao ;
Mo, Qin-Guo ;
Wei, Chang-Yuan ;
Qin, Qing-Hong ;
Huang, Zhen ;
He, Jie .
ONCOLOGY LETTERS, 2013, 5 (03) :983-991
[10]  
Oliva J, 2012, UBD UBIQUITIN D